GR1008842B - Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου - Google Patents

Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου

Info

Publication number
GR1008842B
GR1008842B GR20150100356A GR20150100356A GR1008842B GR 1008842 B GR1008842 B GR 1008842B GR 20150100356 A GR20150100356 A GR 20150100356A GR 20150100356 A GR20150100356 A GR 20150100356A GR 1008842 B GR1008842 B GR 1008842B
Authority
GR
Greece
Prior art keywords
preparation
atypical antipsychotic
factor
pharmaceutical formulation
formulation containing
Prior art date
Application number
GR20150100356A
Other languages
English (en)
Inventor
Ευθυμιος Χρηστου Κουτρης
Ιωαννα Χρηστου Κουτρη
Αναστασια Λεωνιδα Καλασκανη
Βασιλικη Χρηστου Σαμαρα
Μορφης Νικολαου Αμπατζης
Ευαγγελος Ανδρεα Καραβας
Χριστινα-Χρυση Ηλια Κιζιριδη
Ληδα Ευαγγελου Καλαντζη
Original Assignee
Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων filed Critical Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων
Priority to GR20150100356A priority Critical patent/GR1008842B/el
Priority to PL16742161T priority patent/PL3331505T3/pl
Priority to ES16742161T priority patent/ES2818249T3/es
Priority to PCT/EP2016/001164 priority patent/WO2017020984A1/en
Priority to HUE16742161A priority patent/HUE051301T2/hu
Priority to DK16742161.9T priority patent/DK3331505T3/da
Priority to PT167421619T priority patent/PT3331505T/pt
Priority to EP16742161.9A priority patent/EP3331505B1/en
Priority to US15/749,469 priority patent/US20180214381A1/en
Publication of GR1008842B publication Critical patent/GR1008842B/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά φαρμακευτικά σκευάσματα ελεγχόμενης αποδέσμευσης αποτελούμενα από έναν άτυπο αντιψυχωσικό παράγοντα, όπως Παλιπεριδόνη ή κάποιο φαρμακευτικά αποδεκτό άλας αυτής, υπό την μορφή δισκίου πολλαπλών στοιβάδων, που παρέχει αποδέσμευση φαρμάκου μηδενικής τάξεως. Επίσης, η εφεύρεση αφορά και την μέθοδο παρασκευής του ως άνω σκευάσματος.
GR20150100356A 2015-08-06 2015-08-06 Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου GR1008842B (el)

Priority Applications (9)

Application Number Priority Date Filing Date Title
GR20150100356A GR1008842B (el) 2015-08-06 2015-08-06 Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου
PL16742161T PL3331505T3 (pl) 2015-08-06 2016-07-07 Kompozycja farmaceutyczna zawierająca atypowy środek przeciwpsychotyczny i sposób jej wytwarzania
ES16742161T ES2818249T3 (es) 2015-08-06 2016-07-07 Composición farmacéutica que comprende un agente antipsicótico atípico y método para su preparación
PCT/EP2016/001164 WO2017020984A1 (en) 2015-08-06 2016-07-07 Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
HUE16742161A HUE051301T2 (hu) 2015-08-06 2016-07-07 Atipikus antipszichotikus szert tartalmazó gyógyászati készítmény és eljárás annak elõállítására
DK16742161.9T DK3331505T3 (da) 2015-08-06 2016-07-07 Farmaceutisk sammensætning, som omfatter et atypisk antipsykotisk middel og en fremgangsmåde til fremstilling deraf
PT167421619T PT3331505T (pt) 2015-08-06 2016-07-07 Composição farmacêutica compreendendo um agente antipsicótico atípico e método para a sua preparação
EP16742161.9A EP3331505B1 (en) 2015-08-06 2016-07-07 Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof
US15/749,469 US20180214381A1 (en) 2015-08-06 2016-07-07 Pharmaceutical composition comprising an atypical antipsychotic agent and method for the preparation thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GR20150100356A GR1008842B (el) 2015-08-06 2015-08-06 Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου

Publications (1)

Publication Number Publication Date
GR1008842B true GR1008842B (el) 2016-09-05

Family

ID=56550161

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20150100356A GR1008842B (el) 2015-08-06 2015-08-06 Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου

Country Status (9)

Country Link
US (1) US20180214381A1 (el)
EP (1) EP3331505B1 (el)
DK (1) DK3331505T3 (el)
ES (1) ES2818249T3 (el)
GR (1) GR1008842B (el)
HU (1) HUE051301T2 (el)
PL (1) PL3331505T3 (el)
PT (1) PT3331505T (el)
WO (1) WO2017020984A1 (el)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109993A1 (en) * 2008-02-04 2009-09-11 Torrent Pharmaceuticals Ltd. Extended release dosage form of paliperidone
US20100022511A1 (en) * 2008-07-24 2010-01-28 Fang-Yu Liu Stabilized Atypical Antipsychotic Formulation
WO2010089775A2 (en) * 2009-02-05 2010-08-12 Getz Pharma Research Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent
US20130034605A1 (en) * 2011-08-01 2013-02-07 Micro Labs Limited Extended release pharmaceutical compositions containing paliperidone
US20130064889A1 (en) * 2011-09-13 2013-03-14 Aptapharma, Inc. Tablet-in-tablet Palperidone Formulations and Methods for Production and Use Thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE373472T1 (de) 2002-07-29 2007-10-15 Alza Corp Verfahren und dosierformen für die kontrollierte abgabe von paliperidon
WO2007044234A1 (en) 2005-10-07 2007-04-19 Alza Corporation Osmotic dosage form with controlled release and fast release aspects
WO2009025859A1 (en) 2007-08-21 2009-02-26 Teva Pharmaceutical Industries Ltd. Paliperidone sustained release formulation
US20130129827A1 (en) * 2009-10-16 2013-05-23 Ranbaxy Laboratories Limited Extended release pharmaceutical compositions of paliperidone and processes of preparation thereof

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009109993A1 (en) * 2008-02-04 2009-09-11 Torrent Pharmaceuticals Ltd. Extended release dosage form of paliperidone
US20100022511A1 (en) * 2008-07-24 2010-01-28 Fang-Yu Liu Stabilized Atypical Antipsychotic Formulation
WO2010089775A2 (en) * 2009-02-05 2010-08-12 Getz Pharma Research Improved drug dosage form for controlled delivery of one or more pharmaceutically active agent
US20130034605A1 (en) * 2011-08-01 2013-02-07 Micro Labs Limited Extended release pharmaceutical compositions containing paliperidone
US20130064889A1 (en) * 2011-09-13 2013-03-14 Aptapharma, Inc. Tablet-in-tablet Palperidone Formulations and Methods for Production and Use Thereof

Also Published As

Publication number Publication date
HUE051301T2 (hu) 2021-03-01
DK3331505T3 (da) 2020-09-14
WO2017020984A1 (en) 2017-02-09
US20180214381A1 (en) 2018-08-02
PT3331505T (pt) 2020-09-18
PL3331505T3 (pl) 2021-01-25
ES2818249T3 (es) 2021-04-09
EP3331505A1 (en) 2018-06-13
EP3331505B1 (en) 2020-07-15

Similar Documents

Publication Publication Date Title
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PL3224254T3 (pl) Podstawione indazole, sposób ich wytwarzania, preparaty farmaceutyczne je zawierające, oraz ich zastosowanie do wytwarzania leków
HUE051877T2 (hu) Biciklusos származékok, eljárás elõállításukra és ezeket tartalmazó gyógyszerészeti készítmények
PL3515420T3 (pl) Kompozycje farmaceutyczne do zastosowania w terapii zapalenia brzegów powiek
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
HK1231416A1 (zh) 西羅莫司及其衍生物的絡合物、其製備方法以及含有其的藥物組合物
SG11201605868XA (en) Pharmaceutical composition for cancer treatment and pharmaceutical preparation for cancer treatment containing same composition as active ingredient
IL260040A (en) Complexes of celecoxib and its salts and derivatives, a process for their preparation and pharmaceutical preparations containing them
IL250306B (en) Heterocyclyl-carbonyl derivatives of indazole and pyrazolo-pyridine and medicinal preparations containing them
IL252901B (en) Pharmaceutical preparations of tropomyosin-related kinase (trk) inhibitors
IN2014MU01042A (el)
IL266825A (en) Pharmaceutical formulation containing tadalafil
IL262494A (en) A pharmaceutical combination preparation containing Ivacaptor and Lomaceptor complex compositions, their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them
GR1008186B (el) Φαρμακευτικο σκευασμα περιεχον ενα ατυπο αντιψυχωσικο παραγοντα και μεθοδος για την παρασκευη αυτου
GB2546513B (en) Process of preparing active pharmaceutical ingredient salts
MX2017002544A (es) Derivados de isoquinolinona utiles en el tratamiento contra el cancer.
GR1008842B (el) Φαρμακευτικο σκευασμα περιεχον εναν ατυπο αντιψυχωσιμο παραγοντα και μεθοδος για την παρασκευη αυτου
GR1008442B (el) Φαρμακευτικο σκευασμα περιεχον αριπιπραζολη ή αλας αυτης
EP3120848A4 (en) Therapeutic/preventive agent containing coumarin derivative as active ingredient
IL262489A (en) Complexes of ivacaptor and its salts and their history, a process for their preparation and pharmaceutical preparations containing them
IL262490A (en) Lomacaptor complexes and their salts and derivatives, a process for their preparation and pharmaceutical preparations containing them
HK1244703A1 (zh) 一種含有咪唑啉類衍生物的藥物組合物
GR1008380B (el) Φαρμακευτικο σκευασμα περιεχον ενα αντιικο παραγοντα και μεθοδος για την παρασκευη αυτου
GB201414271D0 (en) Composition for delivery of an active pharmaceutical substance and method of preparing same
IN2014CH00984A (el)

Legal Events

Date Code Title Description
PG Patent granted

Effective date: 20161020